<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew M Kaunitz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 16, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormal uterine bleeding (AUB), a term that refers to menstrual bleeding of abnormal quantity, duration, or schedule, is a common gynecologic problem. Heavy or prolonged uterine bleeding can result in anemia, interfere with daily activities, and is the most common presenting symptom in patients with endometrial hyperplasia or carcinoma. It may also be a sign of an underlying bleeding disorder.
        </p>
        <p>
         Most patients with AUB requiring medical attention can be managed in an outpatient setting. Occasionally, an exacerbation of AUB is severe enough to necessitate emergency medical care.
        </p>
        <p>
         The management of non-acute AUB in nonpregnant reproductive-age patients will be reviewed here. Other related topics are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation and diagnosis of AUB (see
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of acute AUB (see
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation and management of AUB in adolescents (see
         <a class="medical medical_review" href="/z/d/html/116.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaginal bleeding during pregnancy (see
         <a class="medical medical_review" href="/z/d/html/6799.html" rel="external">
          "Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postmenopausal bleeding (see
         <a class="medical medical_review" href="/z/d/html/5421.html" rel="external">
          "Approach to the patient with postmenopausal uterine bleeding"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AUB encompasses a heterogeneous group of conditions with diverse etiologies. The International Federation of Gynecology and Obstetrics (FIGO) classification system includes two systems for AUB: FIGO system 1 for the nomenclature and definitions of normal and abnormal uterine bleeding, and FIGO system 2 for the classification of the causes of AUB [
         <a href="#rid1">
          1,2
         </a>
         ]. The latter is referred to by the acronym PALM-COEIN (polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not yet classified). These are summarized in the graphics  (
         <a class="graphic graphic_table graphicRef103238" href="/z/d/graphic/103238.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef90483" href="/z/d/graphic/90483.html" rel="external">
          figure 1
         </a>
         ) and discussed in detail separately.
        </p>
        <p class="headingAnchor" id="H781002136">
         <span class="h1">
          MANAGEMENT GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main goals of AUB management are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correct or treat the underlying primary etiology, if present and feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improve quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent an episode of acute uterine bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent, or treat, anemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Establish a regular bleeding pattern (or amenorrhea).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent endometrial hyperplasia/carcinoma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H914515114">
         <span class="h1">
          CONSIDERATIONS PRIOR TO INITIATING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         To help determine which treatment is best for a particular patient, clinicians should consider several patient factors. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Etiology, if known. The timing of initiating treatment of AUB should be individualized. In patients in whom AUB is not interfering with daily activities, it may be appropriate to delay initiation of treatment until results of diagnostic testing (eg, blood count, imaging, endometrial biopsy) are available. (See
         <a class="local">
          'Patients with a known primary etiology'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Endometrial sampling: Choice of modality'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">
          "Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Premenopausal patients with abnormal bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, when AUB is interfering with daily activities and/or marked anemia is present, it is appropriate to immediately initiate treatment, as detailed below, while pursuing diagnostic testing. (See
         <a class="local">
          'Treatment selection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severity of bleeding. Most patients with AUB requiring medical attention can be managed in an outpatient setting. By contrast, patients with an episode of acute uterine bleeding may require urgent evaluation in an emergency department. (See
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated symptoms and issues. AUB is often associated with other symptoms (eg, pelvic pain/pressure, dysmenorrhea) or issues (eg, infertility); the underlying etiology (eg, adenomyosis, uterine fibroid) should be identified to select the optimal treatment approach. Patients with a bleeding disorder may have a history of other bleeding (eg, nose bleeds, bruising, excessive bleeding after a dental procedure) that they may not report to their gynecologist. (See
         <a class="local">
          'Patients with a known primary etiology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraceptive needs and plans for future pregnancy. Many treatments for AUB also provide contraception. However, for patients trying to conceive, or those desiring pregnancy in the near future, some treatments (eg,
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel intrauterine device
         </a>
         [IUD], depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [DMPA]) should be avoided. (See
         <a class="local">
          'Patients trying to conceive'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical comorbidities. Some treatments (eg, estrogen-progestin contraceptives) are contraindicated in patients with comorbidities (eg, elevated risk for venous thromboembolic disease and/or arterial thrombotic events). (See
         <a class="local">
          'Preferred approach for most patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient preferences regarding, as well as access to, medical versus surgical and short-term versus long-term therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Time to menopause. AUB should resolve when a patient becomes menopausal (which occurs, on average, at the age of 51.5 years), and time to menopause may affect management decisions. (See
         <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">
          "Clinical manifestations and diagnosis of menopause", section on 'Menopause'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Expectant management may be reasonable for some patients (eg, not anemic, do not desire treatment, approaching menopause). Such patients require close follow-up (eg, ferritin level every 6 to 12 months for patients with heavy menstrual bleeding (HMB), repeat endometrial assessment for patients at risk for hyperplasia/neoplasia).
        </p>
        <p class="headingAnchor" id="H2708205196">
         <span class="h1">
          TREATMENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_algorithm graphicRef138483" href="/z/d/graphic/138483.html" rel="external">
          algorithm 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3267366119">
         <span class="h2">
          Patients with a known primary etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of certain underlying conditions may correct the AUB or make further treatment more effective. These include structural lesions (eg, submucosal fibroids, polyps), endocrine (eg, polycystic ovarian syndrome), infectious (eg, chronic endometritis), or bleeding disorders.
        </p>
        <p class="headingAnchor" id="H1907256199">
         <span class="h3">
          Structural lesions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Submucosal fibroids
         </strong>
         are a common cause of heavy menstrual bleeding (HMB) and can be treated with medical or surgical therapies. (See
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endometrial polyps
         </strong>
         are
         <strong>
         </strong>
         a common cause of AUB and are typically easily removed with hysteroscopic polypectomy. (See
         <a class="medical medical_review" href="/z/d/html/5457.html" rel="external">
          "Endometrial polyps"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adenomyosis
         </strong>
         is a common cause of HMB and dysmenorrhea; while hysterectomy is the definitive treatment, medical or other surgical therapies may also be effective.
         <strong>
         </strong>
         (See
         <a class="medical medical_review" href="/z/d/html/5489.html" rel="external">
          "Uterine adenomyosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cesarean scar defects
         </strong>
         (CSD; also referred to as isthmocele or niche) is an increasingly common cause of AUB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CSD can be surgically resected via operative hysteroscopy, vaginal surgery, laparotomy/laparoscopy, or a combined approach (which allows visualization of the defect from two perspectives). In one meta-analysis including randomized trials and observational studies of surgical treatment for CSD, those undergoing a combined approach with laparoscopy and hysteroscopy compared with vaginal surgery or hysteroscopy alone had a greater reduction in the duration of AUB [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arteriovenous malformations
         </strong>
         (AVMs) represent a rare cause of AUB. (See
         <a class="medical medical_review" href="/z/d/html/5440.html" rel="external">
          "Causes of female genital tract bleeding", section on 'Not otherwise classified (AUB-N)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If bleeding is severe, initial management consists of hemodynamic stabilization with intrauterine tamponade (eg, with a balloon or packing material) followed by uterine artery embolization (UAE  (
         <a class="graphic graphic_diagnosticimage graphicRef76350 graphicRef55273 graphicRef69077 graphicRef76792 graphicRef57864" href="/z/d/graphic/76350.html" rel="external">
          image 1A-E
         </a>
         )). While UAE appears to be safe and effective [
         <a href="#rid4">
          4-7
         </a>
         ], and both restoration of normal menstrual cycles and subsequent successful pregnancies have been reported, patients should be counseled that embolization may result in impaired fertility and the safety of pregnancy after embolization is uncertain [
         <a href="#rid8">
          8,9
         </a>
         ]. Laparoscopic bipolar coagulation of the uterine vessels has also been successful in case reports [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding", section on 'Role of uterine artery embolization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hysterectomy is the definitive treatment option in patients in whom childbearing is complete [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of enhanced myometrial vascularity (EMV), a diagnostic entity distinct from AVM and occurring in the setting of pregnancy and retained products of conception, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5482.html" rel="external">
          "Retained products of conception in the first half of pregnancy", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113133.html" rel="external">
          "Secondary (late) postpartum hemorrhage", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3271886609">
         <span class="h3">
          Infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         AUB in patients with suspected or documented chronic endometritis often resolves following a course of antibiotics. (See
         <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">
          "Endometritis unrelated to pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H190201733">
         <span class="h3">
          Endocrine abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine abnormalities (eg, hypothyroidism, hyperprolactinemia) may cause anovulatory bleeding (AUB-O), and treatment often restores regular ovulatory cycles; treatment of other endocrine abnormalities (eg, polycystic ovarian syndrome) can also help decrease the risk of endometrial hyperplasia or carcinoma [
         <a href="#rid12">
          12-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H503246681">
         <span class="h3">
          Bleeding disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         HMB is a common finding in females with a bleeding disorder. Generally, therapy tailored to the bleeding disorder is preferable to other medical or surgical therapies for AUB [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5440.html" rel="external">
          "Causes of female genital tract bleeding", section on 'Coagulopathy (AUB-C)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Interventions for HMB'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3668725816">
         <span class="h2">
          Patients without a known etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         While many patients with AUB will be diagnosed with a primary etiology (see
         <a class="local">
          'Patients with a known primary etiology'
         </a>
         above), patients without a primary etiology also have AUB. Initial management of such patients typically consists of progestin-based treatments including combination oral contraceptives (OCs) or the 52 mg levonorgestrel-releasing intrauterine device (LNG 52 mg IUD, Mirena or Liletta  (
         <a class="graphic graphic_algorithm graphicRef138483" href="/z/d/graphic/138483.html" rel="external">
          algorithm 1
         </a>
         )). Alternatives for selected patients include progestin-only oral or injectable medications, nonhormonal therapies, minimally invasive surgery, or definitive treatment with hysterectomy; however, surgical options are limited in patients who desire future childbearing.
        </p>
        <p class="headingAnchor" id="H2973472420">
         <span class="h3">
          Preferred approach for most patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with AUB and no known primary etiology, we suggest estrogen-progestin contraceptives or the LNG 52 mg as first-line therapy. Both estrogen-progestin contraceptives and the LNG 52 mg are effective treatments for AUB, provide effective contraception, are well tolerated, and have a low risk of adverse effects. (See
         <a class="local">
          'Estrogen-progestin contraceptives'
         </a>
         below and
         <a class="local">
          'Levonorgestrel intrauterine device'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2259394498">
         <span class="h4">
          How to choose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice between the two methods depends on several factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with a contraindication to estrogen
         </strong>
         – For patients with a contraindication to contraceptive doses of estrogen, estrogen-progestin contraceptives are not an option; this includes patients with the following characteristics [
         <a href="#rid18">
          18,19
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥35 years and smoking ≥15 cigarettes per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple risk factors for arterial cardiovascular disease (such as older age, smoking, diabetes, and hypertension). Because age and obesity represent independent risk factors for venous thromboembolism (VTE) [
         <a href="#rid20">
          20,21
         </a>
         ], in our practice, we also avoid estrogen-progestin contraceptives in patients ≥40 years of age with obesity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VTE.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Known thrombogenic mutations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Known ischemic heart disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of stroke.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic lupus erythematosus (positive or unknown antiphospholipid antibodies).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Migraine with aura at any age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The LNG 52 mg is often appropriate for such patients, but medical consultation may be required prior to use. The LNG 52 mg results in a low level of systemic progestin absorption and its use has not been associated with an elevated risk of VTE in average-risk patients [
         <a href="#rid22">
          22
         </a>
         ]. The LNG 52 mg also does not appear to increase the risk of VTE in patients with elevated risk of thrombosis [
         <a href="#rid23">
          23
         </a>
         ]. In a case-control study including reproductive age patients with (21,405) and without (107,025) VTE, current use of LNG 52 mg compared with non-use was associated with similar rates of VTE; results were also similar after controlling for 16 VTE risk factors (including, but not limited to, BMI ≥30 kg/m
         <sup>
          2
         </sup>
         , smoking, hypertension, and superficial venous thrombosis) [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias", section on 'Progestin-only methods'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient preference
         </strong>
         – For other patients, the choice is often based on patient preference. Patients may prefer estrogen-progestin contraceptives if they prefer taking a daily oral medication, regular bleeding, or are planning to conceive in the near future. By contrast, patients may prefer the low maintenance of having an IUD or are willing to tolerate the irregular bleeding that initially accompanies placement of a LNG 52 mg given the subsequent light bleeding or amenorrhea that often occurs. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Counseling points'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection", section on 'Reasons to choose an LNG IUD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In systematic reviews and a meta-analysis including randomized trials, the LNG 52 mg reduced menstrual blood loss more than other medical treatments, however, the certainty of this evidence was low [
         <a href="#rid25">
          25-29
         </a>
         ]. In one review including patients with HMB, placement of a LNG 52 mg resulted in a greater reduction in menstrual blood loss (71 to 95 percent reduction) than estrogen-progestin contraceptives (35 to 69 percent reduction) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1448583304">
         <span class="h4">
          Estrogen-progestin contraceptives
         </span>
         <span class="headingEndMark">
          —
         </span>
         For many patients with AUB, estrogen-progestin contraceptives are first-line management. The advantages of estrogen-progestin contraceptives are that they typically make bleeding more regular, lighter, and reduce dysmenorrhea, as well as provide contraception. Randomized trials including patients with AUB have shown improvement in bleeding patterns compared with placebo (47 versus 9 percent) [
         <a href="#rid25">
          25
         </a>
         ], and reductions in menstrual blood loss ranging from 35 to 69 percent [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The only OC approved by the US Food and Drug Administration (FDA) for treatment of HMB is
         <a class="drug drug_general" data-topicid="15573" href="/z/d/drug information/15573.html" rel="external">
          estradiol-dienogest
         </a>
         (Natazia; includes 2 to 3 mg of estradiol valerate [dose varies and is equivalent to 1.5 to 2.25 mg of micronized oral estradiol or &lt;20 mcg of ethinyl estradiol [
         <a href="#rid30">
          30
         </a>
         ]]), which has 26 hormonally active tablets per each 28-day pill pack. In a randomized placebo-controlled trial including 190 patients with AUB (more than three-quarters of whom had documented HMB; the remainder had prolonged or frequent bleeding), estradiol-dienogest compared with placebo reduced menstrual blood loss in more patients (64 versus 8 percent) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In addition to
         <a class="drug drug_general" data-topicid="15573" href="/z/d/drug information/15573.html" rel="external">
          estradiol-dienogest
         </a>
         , there are many other formulations of estrogen-progestin contraceptives that vary by the type, dose, route, and schedule  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 2
         </a>
         ); it appears that most formulations are effective for treating HMB, and for regulating bleeding and providing endometrial protection in patients with AUB-O:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          By type
         </strong>
         – While many other OC types are available, they have not been directly compared with
         <a class="drug drug_general" data-topicid="15573" href="/z/d/drug information/15573.html" rel="external">
          estradiol-dienogest
         </a>
         ; thus, it is uncertain whether estradiol-dienogest has greater efficacy than other OCs in reducing menstrual blood loss in patients with HMB. OCs with shorter hormone-free intervals are associated with less withdrawal bleeding than formulations with seven hormone-free days per 28-day pill pack [
         <a href="#rid32">
          32
         </a>
         ]. Although further study is needed to determine which OC formulations are more effective in treating HMB, our preference is to use formulations with four or fewer hormone-free days per pill pack.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          By route
         </strong>
         – Other routes of administration include the transdermal contraceptive patch (eg, Xulane, Twirla) and vaginal contraceptive ring (eg, NuvaRing, Annovera). Although these have not been studied extensively for HMB, it is likely that the efficacy of these in treating AUB is similar to OCs, and the choice of delivery system depends on patient preference [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          By schedule
         </strong>
         – Estrogen-progestin contraceptives may be prescribed in a cyclic (with a monthly withdrawal bleed), extended (eg, with a withdrawal bleeding every three months), or continuous (no withdrawal bleed) regimen. Although extended or continuous contraceptive use may more effectively suppress menstrual blood loss, unscheduled (breakthrough) bleeding is more common with this approach than with cyclic dosing, limiting this strategy's appeal for some patients. In clinical trials performed in patients with normal menses, extended-cycle OC formulations that replace hormonally inactive tablets with low-dose ethinyl estradiol, a formulation which also modifies the ethinyl estradiol dose during each three-month pill pack, appear to reduce unscheduled bleeding [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Hormone components'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">
          "Hormonal contraception for menstrual suppression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Estrogen-progestin contraceptives are contraindicated in patients who are at elevated risk for thrombosis. (See
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H664831173">
         <span class="h4">
          Levonorgestrel intrauterine device
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with HMB who do not desire pregnancy in the near future, or for those with a contraindication to estrogen, the
         <strong>
         </strong>
         LNG 52 mg is often used as first-line management [
         <a href="#rid36">
          36
         </a>
         ], and is approved by the FDA for this indication [
         <a href="#rid37">
          37,38
         </a>
         ]. Further study is needed to determine the efficacy of other progestin IUDs (eg, 19.5 mg and 13.5 mg LNG devices) in treating HMB [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection"
         </a>
         .)
        </p>
        <p>
         Factors specific to treatment of HMB with the LNG 52 mg include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduction of bleeding
         </strong>
         – Most patients using the LNG 52 mg develop scant bleeding or amenorrhea, and some studies suggest this treatment, compared with other hormonal or nonhormonal treatments, is associated with an improved quality of life [
         <a href="#rid40">
          40-42
         </a>
         ]. In studies of patients with HMB, within three months of IUD placement, most patients experience spotting [
         <a href="#rid43">
          43-45
         </a>
         ]. At six months, menstrual suppression is substantially greater, with most patients experiencing amenorrhea or infrequent bleeding; median hemoglobin and ferritin levels also increased from baseline (7.5 and 68.8 percent, respectively). In one retrospective study including 89 patients with HMB in whom follow-up data were available, treatment with the LNG 52 resulted in a median decrease in blood loss of 93 and 98 percent at three and six months, respectively [
         <a href="#rid42">
          42
         </a>
         ]. Results were similar for patients with body mass index (BMI) &lt;30 compared with ≥30 kg/m
         <sup>
          2
         </sup>
         and for nulliparous compared with parous patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Furthermore, users of the LNG 52 mg require fewer subsequent additional interventions. In one large observational study, increasing use of the LNG 52 mg (a 14-fold increase over 22 years) was accompanied by a decrease in use of oral
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , oral progestogen, and hysterectomy [
         <a href="#rid46">
          46
         </a>
         ]. These observations underscore the efficacy of the LNG 52 mg in preventing and/or treating AUB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of expulsion
         </strong>
         – Expulsion rates are higher in patients using the LNG 52 mg for treatment of HMB compared with those using the device specifically for contraception (up to 20 versus 10 percent, respectively) [
         <a href="#rid47">
          47,48
         </a>
         ]. For patients with adenomyosis, one study reported a 25 percent expulsion rate with the LNG 52 mg [
         <a href="#rid49">
          49
         </a>
         ]. Package labeling for the LNG 52 mg lists congenital or acquired distortion of the endometrial cavity (eg, by fibroids) as a contraindication to placement of this IUD. Nonetheless, in patients with HMB who wish to avoid surgery or in whom the risk of surgical complications is elevated, use of the LNG 52 mg may be appropriate in well-counseled patients. When placing the LNG 52 mg in patients with a distorted endometrial cavity, some clinicians use abdominal ultrasound guidance to ensure optimal placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of replacing the device
         </strong>
         – When the LNG 52 mg is used to treat HMB, it is approved by the FDA for five years [
         <a href="#rid37">
          37,38
         </a>
         ]. By contrast, when the LNG 52 mg is used for contraception, it is approved for eight years. Thus, menstrual suppression may attenuate before it needs to be removed for contraception, and patients using the LNG 52 mg for treatment of HMB may benefit from more frequent removal and replacement of the device [
         <a href="#rid36">
          36
         </a>
         ]. The need for more frequent replacement may reflect declining intrauterine progestin concentrations during use of this device. (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3731639415">
         <span class="h3">
          Other patients
         </span>
        </p>
        <p class="headingAnchor" id="H2683764544">
         <span class="h4">
          Patients who cannot or choose not to use a preferred method
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who choose not to, or cannot, use a preferred method, alternatives include other progestin-therapies (eg, oral progestins, depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [DMPA]), noncontraceptive doses of estrogen-progestin, and nonhormonal therapies (eg,
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , nonsteroidal antiinflammatory drugs [NSAIDs]). While oral or injectable progestin-only therapies are also reasonable first-line treatment options, they often initially result in irregular menses and are associated with side effects (eg, dysphoria, bloating, increased appetite) that some patients find bothersome. Thus, these medications tend to be used as an alternative to estrogen-progestin contraceptives or LNG 52 mg for selected patients.
        </p>
        <p>
         Such medical treatments reduce menstrual blood loss less than the LNG 52 mg (see
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above). In one systematic review of randomized trials, the percent reduction of menstrual blood loss by treatment method was as follows: LNG 52 mg: 71 to 95 percent reduction; cyclical oral progestins: 87 percent reduction;
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         : 26 to 54 percent reduction; and NSAIDs: 10 to 52 percent reduction [
         <a href="#rid26">
          26
         </a>
         ]. Similarly, a subsequent systematic review showed the largest reduction of menstrual blood loss with the LNG 52 mg (mean difference [MD] -106 mL/cycle) compared with antifibrinolytic (MD -80 mL/cycle), oral progestin (MD -77 mL/cycle), and NSAID (MD -41 mL/cycle) therapy [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4014628327">
         <span class="h5">
          Other progestin-only therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other progestin therapies (ie, oral progestins,
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         ) are less well studied for the treatment of AUB.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral progestin
         </strong>
         formulations (eg,
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         acetate [NETA],
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [MPA]) are generally used to treat AUB in patients who have contraindications to, or prefer to avoid, estrogen
         <strong>
          and
         </strong>
         who prefer not to use, or do not have access to, the LNG 52 mg, or patients who desire pregnancy in the near future (see
         <a class="local">
          'Patients trying to conceive'
         </a>
         below). Package labeling for such oral progestins list a history of VTE as a contraindication to use as they are partially metabolized to ethinyl estradiol [
         <a href="#rid50">
          50
         </a>
         ], which may elevate risk of VTE; thus, medical consultation may be helpful to determine VTE risk. In the case-control study discussed above (see
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above), use of NETA or MPA was associated with higher rates of VTE compared with non-use (adjusted odds ratio [aOR] 3, 95% CI 2.17-4.15 and 1.98, 95% CI 1.53-2.58, respectively) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dose
         </strong>
         – The dose of such progestins varies and includes NETA 5 mg orally one to three tablets daily and MPA 5 to 30 mg orally daily. In our practice, we typically start with NETA 5 mg once daily; higher doses within these ranges are typically used in patients with obesity. If bleeding does not resolve, the dose is increased (eg, NETA: by 5 mg increments every one to three months to a maximum dose of 15 mg/day; MPA: by 5 to 10 mg increments every one to three months to a maximum dose of 30 mg/day), and the LNG 52 mg should be more strongly considered (see
         <a class="local">
          'Levonorgestrel intrauterine device'
         </a>
         above). In patients in whom bleeding resolves, we slowly taper the dose down (eg, NETA: by 2.5 mg increments every month as tolerated; MPA: by 5 mg increments every month as tolerated), to reduce side effects and risk of VTE. Similarly, if cost or side-effect considerations in a specific patient preclude use of one agent, the other agent may be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Most data about use of oral progestins for HMB have evaluated NETA, and compared with MPA, it is substantially more potent in promoting endometrial suppression [
         <a href="#rid51">
          51
         </a>
         ]. In one study, the potency of NETA was ten times that of MPA [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Schedule
         </strong>
         – While there are no high-quality data comparing cyclic and continuous progestin therapy for treatment of AUB, we can extrapolate from the LNG 52 mg and
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         that
         <strong>
          continuous
         </strong>
         progestin regimens effectively reduce uterine bleeding. In our experience, we find that continuous rather than cyclical progestin therapy is more effective at reducing blood loss and easier for patients to comply with. Cyclic regimens may be used in select patients (eg, cannot tolerate a continuous regimen, trying to conceive). (See
         <a class="local">
          'Patients trying to conceive'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a mixed population of older reproductive-age patients with AUB-O or HMB, one study found that oral MPA5 mg tablets administered continuously for two months reduced menstrual blood loss by 33 percent [
         <a href="#rid53">
          53
         </a>
         ]. By contrast, a systematic review including six randomized trials evaluating oral progestins administered cyclically for 7 to 11 days each month did
         <strong>
          not
         </strong>
         find this regimen to be effective in ovulatory patients with HMB [
         <a href="#rid54">
          54
         </a>
         ]. However, longer cyclic therapy (eg, 21 days each month) may be effective [
         <a href="#rid33">
          33,55
         </a>
         ] and result in moderate, predictable withdrawal bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The contraceptive efficacy of these regimens has not been evaluated, and a back-up method (eg, barrier contraceptives) is recommended if needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         is typically used for patients with AUB who have contraindications to, or prefer to avoid, estrogen
         <strong>
          and
         </strong>
         who prefer not to use, or do not have access to, the LNG 52 mg, or if they prefer this method of contraception. Some data suggest an increased risk of thrombosis with DMPA [
         <a href="#rid24">
          24,56,57
         </a>
         ]. This is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         is
         <strong>
          not
         </strong>
         an option for patients who are trying to conceive or interested in conceiving in the next one to two years as the contraceptive effect persists for longer than the three-month dosing interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         results in a reduction in bleeding in most patients. In patients with no complaints of AUB at baseline and using DMPA for contraception, approximately one-half become amenorrheic after four injections (one year), and approximately three-quarters of users will become amenorrheic after eight injections (two years). In patients using DMPA for treatment of AUB-O or HMB, one short-term study noted a 49 percent reduction in menstrual blood loss after two months [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Neither progestin-only contraceptive pills (eg,
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         0.35 mg,
         <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">
          drospirenone
         </a>
         ) nor the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         are known to be effective in treating HMB.
        </p>
        <p class="headingAnchor" id="H1424989078">
         <span class="h5">
          Role of noncontraceptive estrogen-progestin formulations
         </span>
         <span class="headingEndMark">
          —
         </span>
         For selected patients with AUB who have
         <strong>
          relative
         </strong>
         contraindications to contraceptive doses of estrogen (eg, patients over age 35 years with obesity, hypertension, diabetes, or who smoke cigarettes)
         <strong>
          and
         </strong>
         who prefer not to use, or do not have access to, the LNG 52 mg or oral progestin therapy, off-label use of ultra-low estrogen dose formulations marketed for treatment of menopausal vasomotor symptoms (eg, ethinyl estradiol 5 mcg with 1 mg of
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         acetate [Jinteli 1/5 and other generics]) may be an option [
         <a href="#rid58">
          58
         </a>
         ]. In our experience, use of this formulation in patients with AUB often results in amenorrhea after several months.
        </p>
        <p>
         Ultra-low estrogen formulations contain 28 days of hormonally active tablets (continuous therapy) with estrogen doses lower than the typical OC dose (20 to 35 mcg ethinyl estradiol). Because this formulation is not proven to provide effective contraception, patients should be counseled to use concomitant back-up (eg, barrier) contraception if needed. Our experience suggests that progestin-related side effects are less common and less severe with this formulation compared with the higher-dose oral progestin regimens. Such use requires careful assessment, patient counseling, and possible medical consultation regarding thrombotic risk. (See
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4039601970">
         <span class="h5">
          Nonhormonal therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonhormonal therapies (eg,
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , NSAIDs) are useful for patients with HMB without a primary etiology who have contraindications to, or would prefer to avoid, hormonal agents; these therapies do not provide contraception. There is no known contraindication to concurrent use of tranexamic acid and NSAIDs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications
         </strong>
         – The optimal patient population for use of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         is not well defined. Tranexamic acid is approved by the FDA for the treatment of HMB; in our practice, we sometimes use this medication for patients with HMB in whom hormonal therapy is contraindicated (eg, personal history of breast cancer), however, its role in patients with an increased risk of thrombosis is controversial. As an antifibrinolytic agent, it competitively blocks the conversion of plasminogen to plasmin, thereby reducing fibrinolysis. Tranexamic acid is also commonly used to treat heavy menstrual bleeding in individuals with bleeding disorders, especially von Willebrand disease (VWD). Tranexamic acid has been used in Sweden for treatment of HMB since the 1960s. (See
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Interventions for HMB'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dose and
         </strong>
         <strong>
          duration
         </strong>
         –
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         is taken only during menses, rather than daily like estrogen-progestin contraceptives. For patients with normal kidney function, the recommended dose is 1300 mg (two 650 mg tablets) three times daily for as long as five days during menstruation. The dose should be adjusted downwards for patients with impaired kidney function.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Evidence for efficacy
         </strong>
         – In a multicenter randomized trial including almost 200 patients with HMB, participants assigned to
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         compared with placebo had a greater decrease in menstrual blood loss (40 versus 8 percent reduction) [
         <a href="#rid59">
          59
         </a>
         ]. The most common reported adverse effects were menstrual cramps, headache, back pain, and nausea and the frequency of events was similar in both groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         is generally well tolerated; however, long-term use has been associated with thrombosis [
         <a href="#rid60">
          60
         </a>
         ]. FDA labeling for tranexamic acid lists a history of VTE or elevated risk of thrombosis (including current use of combination hormonal contraceptives) as a contraindication to use. However, studies do not confirm a significantly elevated risk of thrombosis [
         <a href="#rid61">
          61,62
         </a>
         ]. Some experts consider tranexamic acid to be reasonable in patients currently using combined hormonal contraceptives, provided additional thrombosis risk factors (eg, obesity, immobility, coagulopathy) are not present [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Representative studies include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A case-control study from Sweden did not identify an association between use of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         and venous thrombosis [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A British case-control study observed that
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         was associated with an elevated risk of thrombosis that did not reach statistical significance. Additionally, anemia associated with HMB itself was also found to be associated with an elevated risk of thrombosis, likely a result of reactive thrombocytosis [
         <a href="#rid64">
          64
         </a>
         ]; this suggests that anemia associated with HMB represents a prothrombotic condition regardless of medication use [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In addition to thrombosis risk, the preference for
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         may depend on cost, which varies from very expensive in the United States to quite inexpensive and available over-the-counter in Sweden [
         <a href="#rid65">
          65
         </a>
         ]. Generic formulations of tranexamic acid are available, which have resulted in this medication becoming less expensive in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonsteroidal antiinflammatory drugs
         </strong>
         – NSAIDs used to treat HMB include
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          naproxen
         </a>
         , and
         <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">
          mefenamic acid
         </a>
         ; they reduce the volume of menstrual blood loss by causing a decline in the rate of prostaglandin (PGE2 and PGF2 alpha) synthesis in the endometrium, leading to vasoconstriction and reduced bleeding [
         <a href="#rid66">
          66,67
         </a>
         ]. NSAIDs are not typically used to treat patients with anovulatory AUB (AUB-O). They are generally also avoided in individuals receiving an anticoagulant or with concern for a bleeding disorder, as they may worsening bleeding (as NSAIDs inhibit platelet function). (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Concomitant antiplatelet medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advantages of NSAIDs include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low risk of adverse effects in otherwise young, healthy, reproductive-age patients. The adverse effects of NSAIDs are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction of dysmenorrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low cost and often available over the counter.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Do not need to be taken daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When used for treatment of HMB, NSAIDs are prescribed to start on the first day of bleeding and should be continued for two to three days or until menstruation ceases. Example regimens include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          Ibuprofen
         </a>
         600 mg two [
         <a href="#rid68">
          68
         </a>
         ] to four times daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          Naproxen
         </a>
         500 mg at onset and three to five hours later, then 250 to 500 mg twice a day [
         <a href="#rid69">
          69-71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">
          Mefenamic acid
         </a>
         500 mg three times per day [
         <a href="#rid72">
          72,73
         </a>
         ]
         <strong>
          or
         </strong>
         500 mg followed by 250 mg every six hours (similar to the dosing used for primary dysmenorrhea) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In systematic reviews of randomized trials including patients with HMB, NSAIDs were more effective than placebo at reducing HMB [
         <a href="#rid27">
          27,29
         </a>
         ]. In this study, the efficacy of
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          naproxen
         </a>
         and
         <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">
          mefenamic acid
         </a>
         in treating HMB were similar.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2861919102">
         <span class="h5">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other therapeutic options (
         <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">
          danazol
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ], intravenous estrogen, gonadotropin-releasing hormone analogs) are available for treatment of AUB but either are less effective or have more adverse effects than more preferred treatment options (see
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above). These therapies are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding", section on 'Alternative: High-dose intravenous estrogen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview", section on 'GnRH analogs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H978418668">
         <span class="h4">
          Patients trying to conceive
         </span>
         <span class="headingEndMark">
          —
         </span>
         When counseling a patient regarding treatment of AUB, it is important to ask whether the patient is planning on trying to conceive a pregnancy in the near future. Treatment of AUB is challenging for such patients, but experts advise that the best option is
         <strong>
          oral
         </strong>
         cyclic progestin therapy (eg,
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         or medroxyprogesterone administered on days 5 to 26 of the menstrual cycle) [
         <a href="#rid33">
          33,55,75,76
         </a>
         ] (see
         <a class="local">
          'Other progestin-only therapies'
         </a>
         above). By contrast,
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         does
         <strong>
          not
         </strong>
         represent an appropriate option for treating patients with AUB who may wish to conceive in the next one to two years as its contraceptive effect persists for long periods of time. Similarly, placement of a LNG 52 mg may not be desirable or cost-effective for patients who are planning to conceive a pregnancy within the upcoming year.
        </p>
        <p>
         For patients with HMB, NSAIDs may also be used but should be stopped upon conception, since they are associated with miscarriage and congenital anomalies [
         <a href="#rid77">
          77
         </a>
         ]. There is insufficient evidence about the safety of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         in pregnancy and animal studies suggest that tranexamic acid may interfere with ovulation [
         <a href="#rid78">
          78,79
         </a>
         ]. (See
         <a class="local">
          'Nonhormonal therapies'
         </a>
         above.)
        </p>
        <p>
         For patients with infertility, AUB should be treated before proceeding with infertility treatments; treatments to induce ovulation will also often correct symptoms of AUB in patients in whom infertility is the result of anovulation. (See
         <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">
          "Overview of ovulation induction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3897144912">
         <span class="h4">
          Patients on anticoagulant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately two-thirds of patients using oral anticoagulant treatment experience AUB [
         <a href="#rid80">
          80
         </a>
         ]. In such patients, anticoagulant therapy is often not the primary etiology of AUB, but rather exacerbates the underlying issue. The presence of AUB is dose dependent. In our experience, AUB occurs more frequently during
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         treatment if the International Normalized Ratio (INR) is &gt;3; adjusting the warfarin dose to achieve an INR range of 2 to 3 (if clinically appropriate) often resolves the AUB. AUB also appears to occur more frequently with
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         than with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         or vitamin K antagonists [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p>
         Patients who are on anticoagulant medications who have heavy, prolonged, or irregular uterine bleeding should be evaluated for the etiology and treated as appropriate. Structural lesions (eg, endometrial polyps, uterine fibroids) may be removed with appropriate perioperative consultation with the clinician prescribing anticoagulation therapy. (See
         <a class="local">
          'Structural lesions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p>
         Our approach to patients on anticoagulant therapy without structural lesions is similar to those with contraindications to estrogen therapy (see
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above). Accordingly, we prefer progestin-only therapies, specifically the LNG 52 mg, for treatment of AUB as well as for contraception [
         <a href="#rid80">
          80
         </a>
         ]. However, in anticoagulated patients, neither estrogen-progestin combination contraceptives nor progestin-only methods appears to increase risk of recurrent venous thrombosis [
         <a href="#rid81">
          81
         </a>
         ]. Thus, if an estrogen-progestin contraceptive is used, it is important to discontinue the contraceptive prior to stopping anticoagulation as the procoagulant effects of combination contraceptives may persist for up to six weeks after stopping them [
         <a href="#rid83">
          83
         </a>
         ]. There is limited published evidence addressing medical management of AUB in patients with a history of VTE using low molecular weight heparin or other newer anticoagulants and further study is needed.
        </p>
        <p class="headingAnchor" id="H2213690460">
         <span class="h3">
          Role of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical therapy (eg, endometrial ablation, hysterectomy) may be an option for some patients with AUB; this includes patients who have completed childbearing, those who prefer to avoid medical therapy, or those who desire definitive therapy (hysterectomy). Surgical therapy is also often performed for patients who have failed or have bothersome side effects from medical therapy. In a systematic review of eight randomized trials including patients with HMB, over half of those assigned to medical treatment underwent surgery by two years [
         <a href="#rid84">
          84
         </a>
         ]. At four-month follow-up, endometrial resection was more effective than oral medication in controlling bleeding (odds ratio [OR] 10.6, 95% CI 5.3-21.3) and less likely to cause side effects (OR 0.2, 95% CI 0.1-0.3). Hysterectomy resulted in greater improvements in mental health at six-month follow-up.
        </p>
        <p>
         For patients considering surgery, the risks and benefits should be compared with the LNG 52 mg, which has many of the advantages of surgery but with a low risk of complications and no recovery time. In the United States, one cost-effective approach is to start with the LNG 52 mg and, if unsuccessful, follow with endometrial ablation and, lastly, hysterectomy. This is based on the comparative efficacy of the LNG 52 mg with the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endometrial ablation
         </strong>
         – Endometrial ablation is a minimally invasive treatment option for patients who have completed childbearing and have heavy or prolonged uterine bleeding despite medical therapy or do not want to use chronic medical therapy [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3316.html" rel="external">
          "Overview of endometrial ablation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both endometrial ablation (performed with resectoscopic or nonresectoscopic techniques) and LNG 52 mg are effective in reducing menstrual blood loss [
         <a href="#rid29">
          29
         </a>
         ]. The decision to use endometrial ablation or LNG 52 mg depends on a patient's preferences regarding treatment factors, such as plans for fertility and contraception, convenience, and risks of anesthesia. Advantages of the LNG 52 mg are that it provides reversible contraceptive, is placed in an office setting and requires no or local anesthesia; one disadvantage is the LNG 52 mg needs to be replaced at regular intervals (see
         <a class="local">
          'Levonorgestrel intrauterine device'
         </a>
         above). By contrast, pregnancy is contraindicated after endometrial ablation, but the procedure does not prevent pregnancy; thus, patients will need to continue to use contraception following ablation. In addition, while endometrial ablation can be performed in an office, it is often performed in an operating room under general anesthesia; but if successful, is performed once and often does not require repeating.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a meta-analysis and systematic reviews of randomized trials, the LNG 52 mg and endometrial ablation had similar reductions of menstrual blood loss as well as similar improvements in quality of life [
         <a href="#rid25">
          25,28
         </a>
         ]. However, patients treated with the LNG 52 mg appear to require more reinterventions. In a randomized trial of 270 patients with HMB, patients treated with the LNG 52 mg compared with endometrial ablation underwent more than twice as many surgical reinterventions (27 versus 10 percent, relative risk 2.64, 95% CI 1.49-4.68), which included endometrial ablation and hysterectomy [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hysterectomy
         </strong>
         – Hysterectomy is the definitive treatment for uterine bleeding. This procedure has a high rate of patient satisfaction because it is curative, is frequently performed after medical management has failed, is not associated with drug-related side effects, and does not require repeated procedures or prolonged follow-up. Hysterectomy also has the advantage of eliminating future risk of uterine and cervical cancer and, in patients who also undergo complete salpingectomy, reduces the risk of developing epithelial ovarian carcinomas. However, hysterectomy has a risk of perioperative complications and, depending on the operative approach, a prolonged recovery. (See
         <a class="medical medical_review" href="/z/d/html/3272.html" rel="external">
          "Hysterectomy (benign indications): Selection of surgical route"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">
          "Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction", section on 'Ovarian cancer risk reduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While hysterectomy is curative, treatment with the LNG 52 mg has several potential short- and long-term advantages, in addition to absence of surgical morbidity and reversibility if patients decide they want to try to conceive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2013 study of 236 patients with HMB that followed patients for 10 years after they were randomized to placement of a LNG 52 mg or hysterectomy, 46 percent of those initially randomized to IUD placement ultimately underwent hysterectomy [
         <a href="#rid87">
          87
         </a>
         ]. Overall, costs were lower among patients initially randomized to the IUD, while health-related quality of life and psychosocial well-being were similar in the two groups. In the same trial, 10-year follow-up reported that patients in the IUD group had lower rates of stress urinary incontinence (34 versus 48 percent) and usage of medications for urinary incontinence (1 versus 12 percent) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As many of the randomized trials comparing treatment modalities for AUB in patients who have completed childbearing are over 10 years old and may have evaluated only open abdominal hysterectomy, further studies are needed to compare laparoscopic hysterectomy with other treatments for AUB.
        </p>
        <p>
        </p>
        <p>
         Use of surgical procedures may also be limited by insurance coverage or medical guidelines; for example, the National Health Service in the United Kingdom advises against routine performance of dilation and curettage and hysterectomy for HMB [
         <a href="#rid89">
          89
         </a>
         ]. Surgical procedures are also costly. In one trial, 63 patients with persistent AUB (median duration four years) who were dissatisfied with cyclic oral progestin therapy were randomized to undergo either hysterectomy or expanded medical therapy (eg, cyclic OCs, NSAIDs, low-dose estrogen-progestin regimens) [
         <a href="#rid90">
          90,91
         </a>
         ]. By 18 months, over 50 percent of those randomized to medical treatment had asked for and received a hysterectomy (median interval to crossing over was six months). At 24 months, mean resource use was higher in the surgical versus medical management arms [
         <a href="#rid92">
          92
         </a>
         ]. Broken down to resource use by treatment received, the costs for medication only, medicine followed by hysterectomy, and hysterectomy only were USD $2595, $6128, and $7024, respectively. However, an undefined cost/benefit is elimination of future risk of endometrial carcinoma in patients undergoing hysterectomy; this should not be overlooked as patients with AUB often have characteristics associated with increased rates of endometrial carcinoma.
        </p>
        <p class="headingAnchor" id="H3267367688">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2101986395">
         <span class="h2">
          Patients with iron deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron deficiency is common in individuals with heavy menstrual bleeding (HMB). (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Blood loss'
         </a>
         .)
        </p>
        <p>
         Testing for iron deficiency and/or iron deficiency anemia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         In addition to treating AUB, patients with iron deficiency (with or without anemia) should have their iron deficiency corrected and undergo appropriate monitoring. This is described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
         However, it is important not to attribute all iron deficiency to menstrual bleeding; individuals with new onset iron deficiency or iron deficiency in an adult &gt;50 years (sometimes younger) should prompt evaluation for other causes, which may include upper gastrointestinal disorders (eg, celiac disease, autoimmune gastritis) or colorectal disorders, including cancer. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Search for source of blood and iron loss'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H411830630">
         <span class="h2">
          Patients with dysmenorrhea or pelvic pain/pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with AUB and dysmenorrhea or pelvic pain/pressure often will be diagnosed with a primary etiology (eg, adenomyosis, uterine fibroid). The optimal approach in these patients is to address both issues with one type of treatment. (See
         <a class="medical medical_review" href="/z/d/html/5489.html" rel="external">
          "Uterine adenomyosis", section on 'Management of symptomatic patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H517319">
         <span class="h1">
          WHEN TO REFER
         </span>
         <span class="headingEndMark">
          —
         </span>
         AUB is a common reason for referral to a gynecologist, and 5 percent of female patients between the ages of 30 and 49 years consult a clinician for evaluation of heavy menstrual bleeding (HMB) [
         <a href="#rid93">
          93-95
         </a>
         ]. Referral to a gynecologist is appropriate for patients with heavy bleeding, persistent bleeding despite treatment, if there is suspicion of malignancy, or if surgery is required. Referral is also appropriate if the patient's primary clinician is not comfortable performing endometrial sampling or placing an intrauterine device.
        </p>
        <p>
         Referral to a bleeding disorders expert is appropriate for patients who report other types of excess bleeding. The likelihood of a bleeding disorder can be assessed using an easy-to-administer (by the clinician or the patient) bleeding assessment tool. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder", section on 'Bleeding history'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder", section on 'Bleeding score'
         </a>
         .)
        </p>
        <p>
         Patients with severe anemia, acute heavy bleeding, or hemodynamic instability should be sent to the emergency department. (See
         <a class="medical medical_review" href="/z/d/html/286.html" rel="external">
          "Approach to the adult with vaginal bleeding in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3751682483">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/141288.html" rel="external">
          "Patient perspective: von Willebrand disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1555589406">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109362.html" rel="external">
          "Society guideline links: Abnormal uterine bleeding"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15420.html" rel="external">
          "Patient education: Heavy periods (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/8401.html" rel="external">
          "Patient education: Abnormal uterine bleeding (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/8405.html" rel="external">
          "Patient education: Heavy or prolonged menstrual bleeding (menorrhagia) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical significance and causes
         </strong>
         – Abnormal uterine bleeding (AUB) is a common gynecologic problem that can result in anemia, interfere with daily activities, and is the most common presenting symptom in patients with endometrial hyperplasia or carcinoma. Heavy menstrual bleeding (HMB) is a common presentation of bleeding disorders such as von Willebrand disease. Most patients with AUB requiring medical attention can be managed in an outpatient setting. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evaluation for the cause is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5440.html" rel="external">
          "Causes of female genital tract bleeding"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management goals
         </strong>
         – The goals of initial therapy are to correct the underlying etiology (if present and feasible), improve quality of life, prevent an episode of acute uterine bleeding, prevent (or treat) anemia, establish a regular bleeding pattern, and prevent endometrial hyperplasia/carcinoma. (See
         <a class="local">
          'Management goals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations prior to treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         To help determine which therapy is best for a particular patient, clinicians should consider several patient factors including: etiology; severity of bleeding (eg, anemia, interference with daily activities); associated symptoms and issues (eg, dysmenorrhea/pelvic pain, infertility); contraceptive needs and plans for future pregnancy; medical comorbidities (eg, risk of venous or arterial thrombosis); patient preferences regarding (and access to) medical versus surgical and short-term versus long-term therapy; and time to menopause. (See
         <a class="local">
          'Considerations prior to initiating treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Expectant management is reasonable for patients who are not anemic, do not desire treatment, or are approaching menopause. (See
         <a class="local">
          'Considerations prior to initiating treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with a known primary etiology
         </strong>
         – For patients with AUB and a known primary etiology (eg, structural lesions, endocrine, infectious, or bleeding disorders), treating the underlying condition (if feasible) before initiating other therapy may correct the AUB or make further treatment more effective  (
         <a class="graphic graphic_algorithm graphicRef138483" href="/z/d/graphic/138483.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Patients with a known primary etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without a known etiology
         </strong>
         (
         <a class="graphic graphic_algorithm graphicRef138483" href="/z/d/graphic/138483.html" rel="external">
          algorithm 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients with AUB and no known etiology, we suggest estrogen-progestin contraceptives or the 52 mg levonorgestrel-releasing intrauterine device (LNG 52 mg IUD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         )). Both estrogen-progestin contraceptives and the LNG 52 mg are effective treatments for AUB, provide effective contraception, are well tolerated, and have a low risk of adverse effects. While the LNG 52 mg is the most effective medical treatment of heavy menstrual bleeding (HMB), logistical and/or financial issues may make this device unavailable for some patients. (See
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above and
         <a class="local">
          'Levonorgestrel intrauterine device'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with AUB who are at an increased risk of venous or arterial thrombosis (eg, history of venous thromboembolism [VTE], known thrombogenic mutations, ≥35 years-old with concomitant smoking ≥15 cigarettes/day, hypertension), therapy with contraceptive doses of estrogen is contraindicated. Thus, for such patients we use the LNG 52 mg. The LNG 52 mg results in a low level of systemic progestin absorption and its use has not been associated with an elevated risk of VTE in average-risk patients. (See
         <a class="local">
          'Preferred approach for most patients'
         </a>
         above and
         <a class="local">
          'Levonorgestrel intrauterine device'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who cannot or choose not to use a preferred method (ie, estrogen-progestin contraceptives, LNG 52 mg), reasonable alternatives may include treatment with other progestin-only therapies (eg, depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [DMPA], oral progestins), noncontraceptive estrogen-progestin formulations, nonhormonal therapies (eg,
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , nonsteroidal antiinflammatory drugs [NSAIDs]), or surgery. Medical consultation is helpful to determine thrombotic risk with these treatments. (See
         <a class="local">
          'Patients who cannot or choose not to use a preferred method'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with AUB who are trying to conceive or planning a pregnancy in the near future, we suggest oral progestin therapy rather than other medical therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         is
         <strong>
          not
         </strong>
         an option for such patients as its contraceptive effect persists for long periods of time; similarly, use of the LNG 52 mg may not be desirable or cost-effective. (See
         <a class="local">
          'Patients trying to conceive'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgical therapies (eg, endometrial ablation, hysterectomy) may be an option for some patients with AUB. The risks and benefits should be compared with the LNG 52 mg, which has many of the advantages of surgery but with a low risk of complications and no recovery time. In the United States, one cost-effective approach is to start with the LNG 52 mg and, if unsuccessful, follow with endometrial ablation and, lastly, hysterectomy. (See
         <a class="local">
          'Role of surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H465517093">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Howard Zacur, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet 2018; 143:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.]. Int J Gynaecol Obstet 2019; 144:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Zhong J, Zhou W, et al. Four Surgical Strategies for the Treatment of Cesarean Scar Defect: A Systematic Review and Network Meta-analysis. J Minim Invasive Gynecol 2020; 27:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badawy SZ, Etman A, Singh M, et al. Uterine artery embolization: the role in obstetrics and gynecology. Clin Imaging 2001; 25:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forssman L, Lundberg J, Scherstén T. Conservative treatment of uterine arteriovenous fistula. Acta Obstet Gynecol Scand 1982; 61:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology 2002; 222:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon JH, Kim GS. Obstetric iatrogenic arterial injuries of the uterus: diagnosis with US and treatment with transcatheter arterial embolization. Radiographics 2002; 22:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow TW, Nwosu EC, Gould DA, Richmond DH. Pregnancy following successful embolisation of a uterine vascular malformation. Br J Obstet Gynaecol 1995; 102:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaens J, Desnyder L, Raat H, et al. Selective transcatheter embolization of a uterine arteriovenous malformation with preservation of the reproductive capacity. J Belge Radiol 1996; 79:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu YC, Liu WM, Yuan CC, Ng HT. Successful treatment of symptomatic arteriovenous malformation of the uterus using laparoscopic bipolar coagulation of uterine vessels. Fertil Steril 2001; 76:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darwish B, Letailleur M, Dietrich G, et al. Hysterectomy for Uterine Arteriovenous Malformation: Laparoscopic View. J Minim Invasive Gynecol 2016; 23:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J 1995; 64:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duckitt K, Shaw RW. Is medical management of menorrhagia obsolete? Br J Obstet Gynaecol 1998; 105:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fender GR, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ 1999; 318:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brignardello-Petersen R, El Alayli A, Husainat N, et al. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Adv 2022; 6:228.
          </a>
         </li>
         <li class="breakAll">
          http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/ (Accessed on December 11, 2014).
         </li>
         <li class="breakAll">
          http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s_cid=rr5904a1_e (Accessed on December 11, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012; 344:e2990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008; 90:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cockrum RH, Soo J, Ham SA, et al. Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age. Obstet Gynecol 2022; 140:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009; 113:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matteson KA, Rahn DD, Wheeler TL 2nd, et al. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol 2013; 121:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013; :CD000400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bofill Rodriguez M, Lethaby A, Jordan V. Progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2020; 6:CD002126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bofill Rodriguez M, Dias S, Jordan V, et al. Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis. Cochrane Database Syst Rev 2022; 5:CD013180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmer CJ, Geurts TB. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur J Drug Metab Pharmacokinet 1999; 24:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011; 117:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007; 75:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012; 85:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portman DJ, Kaunitz AM, Howard B, et al. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive. Contraception 2014; 89:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs 2012; 72:193.
          </a>
         </li>
         <li class="breakAll">
          MIRENA (levonorgestrel-releasing intrauterine system). US Food and Drug Administration (FDA) approved product information. Revised June 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021225s043lbl.pdf (Accessed on July 03, 2023).
         </li>
         <li class="breakAll">
          LILETTA (levonorgestrel-releasing intrauterine system). US Food and Drug Administration (FDA) approved product information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206229s013lbl.pdf (Accessed on July 03, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013; 122:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw V, Vandal AC, Coomarasamy C, Ekeroma AJ. The effectiveness of the levonorgestrel intrauterine system in obese women with heavy menstrual bleeding. Aust N Z J Obstet Gynaecol 2016; 56:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creinin MD, Barnhart KT, Gawron LM, et al. Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device. Obstet Gynecol 2023; 141:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception 2002; 65:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception 2012; 86:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meaidi A, Kuhr Skals R, Alexander Gerds T, et al. Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study. Contraception 2020; 101:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madden T, McNicholas C, Zhao Q, et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: A systematic review. Contraception 2010; 82:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng FS, Wu MY, Yang JH, et al. Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method. Taiwan J Obstet Gynecol 2010; 49:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portman DJ, Symons JP, Wilborn W, Kempfert NJ. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. Am J Obstet Gynecol 2003; 188:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986; 46:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Küçük T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008; 35:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008; :CD001016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345:e4944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon JA, Liu JH, Speroff L, et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003; 188:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:865.
          </a>
         </li>
         <li class="breakAll">
          Barbieri, R, Harvard University, 2017, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009; 116:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorne JG, James PD, Reid RL. Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception? Contraception 2018; 98:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson AL, Ritchie JJ. Severe anemia from heavy menstrual bleeding requires heightened attention. Am J Obstet Gynecol 2015; 213:97.e1.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm190551.htm (Accessed on February 01, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees MC, DiMarzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 1987; 113:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 1981; 88:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mäkäräinen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986; 93:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybo G, Nilsson S, Sikström B, Nygren KG. Naproxen in menorrhagia. Lancet 1981; 1:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005; 112:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 1992; 166:1419.
          </a>
         </li>
         <li class="breakAll">
          PONSTEL® (Mefenamic Acid Capsules, USP). US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/015034s040lbl.pdf (Accessed on September 13, 2022).
         </li>
         <li class="breakAll">
          Dr. Robert Rebar, personal communication, 2013.
         </li>
         <li class="breakAll">
          Dr. Kurt Barnhardt, personal communicaton, 2013.
         </li>
         <li class="breakAll">
          www.reprotox.org (Accessed on December 23, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshimura Y, Santulli R, Atlas SJ, et al. The effects of proteolytic enzymes on in vitro ovulation in the rabbit. Am J Obstet Gynecol 1987; 157:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman G, Dharmarajan AM, Takehara Y, et al. The role of protein kinase-C in gonadotropin-induced ovulation in the in vitro perfused rabbit ovary. Endocrinology 1992; 131:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception 2011; 84:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuelson Bannow BT, Chi V, Sochacki P, et al. Heavy menstrual bleeding in women on oral anticoagulants. Thromb Res 2021; 197:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S. Less menorrhagia for women with VTE. Blood 2016; 127:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006; :CD003855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lethaby A, Penninx J, Hickey M, et al. Endometrial resection and ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2013; :CD001501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beelen P, van den Brink MJ, Herman MC, et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding. Am J Obstet Gynecol 2021; 224:187.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heliövaara-Peippo S, Hurskainen R, Teperi J, et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013; 209:535.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heliövaara-Peippo S, Halmesmäki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG 2010; 117:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacobucci G. NHS proposes to stop funding 17 "unnecessary" procedures. BMJ 2018; 362:k2903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuppermann M, Varner RE, Summitt RL Jr, et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA 2004; 291:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Learman LA, Summitt RL Jr, Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol 2004; 103:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Showstack J, Lin F, Learman LA, et al. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol 2006; 194:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner P, Critchley HO, Lumsden MA, et al. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ 2001; 323:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vessey MP, Villard-Mackintosh L, McPherson K, et al. The epidemiology of hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol 1992; 99:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5476 Version 67.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30198563" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30609040" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31698049" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Four Surgical Strategies for the Treatment of Cesarean Scar Defect: A Systematic Review and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11566093" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Uterine artery embolization: the role in obstetrics and gynecology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7090753" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Conservative treatment of uterine arteriovenous fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11867779" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11796896" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Obstetric iatrogenic arterial injuries of the uterus: diagnosis with US and treatment with transcatheter arterial embolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756213" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pregnancy following successful embolisation of a uterine vascular malformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8958669" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Selective transcatheter embolization of a uterine arteriovenous malformation with preservation of the reproductive capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11730765" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Successful treatment of symptomatic arteriovenous malformation of the uterus using laparoscopic bipolar coagulation of uterine vessels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26404909" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hysterectomy for Uterine Arteriovenous Malformation: Laparoscopic View.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8828563" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of abnormal uterine bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7502405" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Menorrhagia management options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9647144" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Is medical management of menorrhagia obsolete?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10231255" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17106950" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Gynaecological and obstetric management of women with inherited bleeding disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34673921" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34673921" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34673921" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17897305" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11245554" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22577198" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18001734" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35926206" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384127" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23635628" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nonsurgical management of heavy menstrual bleeding: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440779" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32529637" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Progestogen-releasing intrauterine systems for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35638592" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10412891" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422847" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17161118" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22067765" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12954519" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A multicenter, randomized study of an extended cycle oral contraceptive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576794" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268392" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268392" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268392" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24240244" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696346" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The effectiveness of the levonorgestrel intrauterine system in obese women with heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23301731" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Levonorgestrel intrauterine system versus medical therapy for menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37023455" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12057782" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733445" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959906" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31935386" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198262" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Association of age and parity with intrauterine device expulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20682142" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intrauterine device use among women with uterine fibroids: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20708521" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341557" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Formation of ethinyl estradiol in women during treatment with norethindrone acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592236" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2946605" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Assessment of the potency of orally administered progestins in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18390083" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18253983" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cyclical progestogens for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9647148" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162263" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22872710" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548201" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20859150" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20859150" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522029" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : No increased risk of venous thrombosis in women taking tranexamic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19016686" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29477633" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25935784" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Severe anemia from heavy menstrual bleeding requires heightened attention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25935784" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Severe anemia from heavy menstrual bleeding requires heightened attention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3035052" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7225303" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3533137" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1872778" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3523328" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6110836" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Naproxen in menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16045528" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595797" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595797" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595797" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595797" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595797" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2441605" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The effects of proteolytic enzymes on in vitro ovulation in the rabbit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1396326" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The role of protein kinase-C in gonadotropin-induced ovulation in the in vitro perfused rabbit ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21757053" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26696010" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33212377" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Heavy menstrual bleeding in women on oral anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26989185" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Less menorrhagia for women with VTE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625593" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Surgery versus medical therapy for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23990373" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Endometrial resection and ablation techniques for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32795428" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23999423" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20156209" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29967052" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : NHS proposes to stop funding 17 "unnecessary" procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15039411" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121552" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16458625" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11440940" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1622913" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The epidemiology of hysterectomy: findings in a large cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11275041" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
